Key Takeaways
- • Congress advanced bipartisan FDA legislation across both chambers in late July 2026, with the House Energy and Commerce Committee and Senate HELP Committee approving multiple bills focused on generic drugs, biosimilars, and expedited nonprescription drug review ahead of the August recess.
- • Key legislative priorities include the Biosimilar Red Tape Elimination Act (H.R. 5526, S. 1954), the STOP GAMES Act (H.R. 8908) to restrict citizen petitions delaying generic competition, and the Expedited Access to Biosimilars Act (H.R. 9661, S. 1414), all designed to accelerate market entry for lower-cost alternatives.
- • The Senate passed the ACT for ALS Reauthorization Act (S. 4472) on August 4, 2026, requiring FDA to publish a five-year plan for rare neurodegenerative disease therapies through fiscal year 2031, with a House companion bill (H.R. 8205) also advancing.
- • Legislative pathway remains uncertain due to the midterm election backdrop and potential lame duck session dynamics; however, bipartisan momentum signals continued congressional focus on drug pricing and approval streamlining into the next Congress.
- • FY2027 FDA appropriations remain unresolved, with House and Senate considering separate continuing resolutions extending through December 2026, delaying final funding decisions while Congress addresses broader fiscal matters.
Summary
Congress demonstrated sustained bipartisan engagement on FDA policy in the weeks preceding the August 2026 recess, with coordinated committee activity in both chambers advancing legislation designed to accelerate generic drug approvals, expand biosimilar competition, and streamline regulatory pathways for nonprescription medications. The House Energy and Commerce Committee approved five major FDA-focused bills during the week of July 20, 2026, while the Senate HELP Committee completed approvals on multiple companion and standalone measures, reflecting alignment on core cost-containment and market-access objectives.
The legislative agenda centered on reducing regulatory friction for competitive alternatives to brand-name drugs. The Biosimilar Red Tape Elimination Act (H.R. 5526 and Senate companion S. 1954, approved 6/17/26) deem biosimilars interchangeable with reference products and authorize FDA guidance issuance on biosimilar review standards. The STOP GAMES Act (H.R. 8908), approved by the House committee on 7/21/26, grants FDA discretionary authority to summarily deny citizen petitions where the primary purpose is delaying generic competition—a mechanism previously used to extend market exclusivity. The Expedited Access to Biosimilars Act (H.R. 9661, S. 1414) modifies clinical study requirements for biosimilar licensure, reducing data burdens for applicants. Additionally, the Senate approved the Insulin Act of 2026 (S. 4189) on 7/22/26, which amends cost-sharing provisions and incorporates generic and biosimilar acceleration provisions mirroring standalone Senate bills.
The House also passed FDA Modernization Act 3.0 (H.R. 2821) in late July, continuing a multiyear effort to reduce animal testing in medical product development; the Senate had passed its companion version (S. 355) in December 2025. Both chambers advanced the ACT for ALS Reauthorization Act (H.R. 8205 passed House 7/22/26; S. 4472 passed Senate 8/4/26), which reauthorizes research and development programs for amyotrophic lateral sclerosis and rare neurodegenerative diseases through FY2031 and mandates FDA publication of a five-year development and investigational drug access plan.
The House approved the Agriculture, Rural Development, FDA, and Related Agency Appropriations Act 2027 (H.R. 8646) on June 4, 2026, but Senate Appropriations Committee action remains pending. Instead, Congress is contemplating continuing resolutions to fund federal operations past September 30, 2026, with the House proposing extension through December 4, 2026, and the Senate through December 11, 2026. This delay provides additional negotiating time for FY2027 appropriations and broader fiscal matters.
The legislative pathway forward remains opaque given the midterm election environment and lame duck session uncertainty. Nonetheless, the sustained bipartisan focus signals that generic drug acceleration, biosimilar competition, and prescription drug cost containment will remain congressional priorities into the next Congress. These individual bills' ultimate resolution will inform the backdrop for critical user fee reauthorizations scheduled for FY2027 expiration, directly affecting pharmaceutical companies' development timelines and market-access strategies.
The legislative agenda centered on reducing regulatory friction for competitive alternatives to brand-name drugs. The Biosimilar Red Tape Elimination Act (H.R. 5526 and Senate companion S. 1954, approved 6/17/26) deem biosimilars interchangeable with reference products and authorize FDA guidance issuance on biosimilar review standards. The STOP GAMES Act (H.R. 8908), approved by the House committee on 7/21/26, grants FDA discretionary authority to summarily deny citizen petitions where the primary purpose is delaying generic competition—a mechanism previously used to extend market exclusivity. The Expedited Access to Biosimilars Act (H.R. 9661, S. 1414) modifies clinical study requirements for biosimilar licensure, reducing data burdens for applicants. Additionally, the Senate approved the Insulin Act of 2026 (S. 4189) on 7/22/26, which amends cost-sharing provisions and incorporates generic and biosimilar acceleration provisions mirroring standalone Senate bills.
The House also passed FDA Modernization Act 3.0 (H.R. 2821) in late July, continuing a multiyear effort to reduce animal testing in medical product development; the Senate had passed its companion version (S. 355) in December 2025. Both chambers advanced the ACT for ALS Reauthorization Act (H.R. 8205 passed House 7/22/26; S. 4472 passed Senate 8/4/26), which reauthorizes research and development programs for amyotrophic lateral sclerosis and rare neurodegenerative diseases through FY2031 and mandates FDA publication of a five-year development and investigational drug access plan.
The House approved the Agriculture, Rural Development, FDA, and Related Agency Appropriations Act 2027 (H.R. 8646) on June 4, 2026, but Senate Appropriations Committee action remains pending. Instead, Congress is contemplating continuing resolutions to fund federal operations past September 30, 2026, with the House proposing extension through December 4, 2026, and the Senate through December 11, 2026. This delay provides additional negotiating time for FY2027 appropriations and broader fiscal matters.
The legislative pathway forward remains opaque given the midterm election environment and lame duck session uncertainty. Nonetheless, the sustained bipartisan focus signals that generic drug acceleration, biosimilar competition, and prescription drug cost containment will remain congressional priorities into the next Congress. These individual bills' ultimate resolution will inform the backdrop for critical user fee reauthorizations scheduled for FY2027 expiration, directly affecting pharmaceutical companies' development timelines and market-access strategies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.